gutflix
GI learning, personalised

Summary

INVESTIGATING THE EVOLUTION OF THE TREATMENT ALGORITHM OF ULCERATIVE COLITIS PATIENTS

Denise Baldock

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A multi-centre chart review study of ulcerative colitis patients across five European countries over three time points (2018, 2020, 2023) found decreasing adalimumab use and increasing adoption of non-TNF therapies, including as first-line treatment.

KEY POINTS

- Adalimumab use in reported UC patients decreased from 30% in Q1 2018 to 15% in Q3 2020 to 13% in Q1 2023, while non-TNF therapy use increased from 12% to 29% to 43% over the same periods.
- First-line use of non-TNF therapies increased from 5% in Q1 2018 to 12% in Q3 2020 to 25% in Q1 2023, suggesting earlier use of non-TNF products in the treatment algorithm.
- TNF-to-TNF switching decreased from 14% in Q1 2018 to 10% in Q3 2020, while switches from non-TNFs to TNFs increased from 8% to 11%.
- The proportion of first-line patients in the overall sample decreased from 84% in Q1 2018 to 77% in Q3 2020, which the authors suggest could indicate increased propensity to switch patients between therapies sooner.
- The study sampled 207-220 gastroenterologists reporting on 816-880 UC patients across the UK, France, Germany, Italy, and Spain at each time point.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/4c63be5a-743c-11ee-b5ea-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.